Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to
placebo in patients with acute adenoviral keratoconjuncivitis.